Functions and therapeutic interventions of non-coding RNAs associated with TLR signaling pathway in atherosclerosis

• Published in: Cellular signalling 2022-12, Vol.100, p.110471, Article 110471
• Main Authors: Margiana, Ria, Alsaikhan, Fahad, Al-Awsi, Ghaidaa Raheem Lateef, Patra, Indrajit, Sivaraman, Ramaswamy, Fadhil, Ali Abdulhussain, AL-Baghdady, Hawra'a Fadhel Abbas, Qasim, Maytham T., Hameed, Noora M., Mustafa, Yasser Fakri, Hosseini-Fard, Seyedreza
• Format: Article
• Language: English
• Subjects: Atherosclerosis; circRNAs; Inflammation; lncRNA; miRNA; ncRNA; TLR signaling
• ISSN: 0898-6568; 1873-3913; 1873-3913
• DOI: 10.1016/j.cellsig.2022.110471

Nowadays, emerging data demonstrate that the toll-like receptor (TLR) signaling pathway plays an important role in the progression of inflammatory atherosclerosis. Indeed, dysregulated TLR signaling pathway could be a cornerstone of inflammation and atherosclerosis, which contributes to the development of cardiovascular diseases. It is interesting to note that this pathway is heavily controlled by several mechanisms, such as epigenetic factors in which the role of non-coding RNAs (ncRNAs), particularly microRNAs and long noncoding RNAs as well as circular RNAs in the pathogenesis of atherosclerosis has been well studied. Recent years have seen a significant surge in the amount of research exploring the interplay between ncRNAs and TLR signaling pathway downstream targets in the development of atherosclerosis; however, there is still considerable room for improvement in this field. The current study was designed to review underlying mechanisms of TLR signaling pathway and ncRNA interactions to shed light on therapeutic implications in patients with atherosclerosis. [Display omitted] •Inflammation is a major mediator of atherosclerosis.•NcRNAs play a pivotal role in atherosclerosis by modulating TLR pathway mediators such as TLR, MyD88, NF-kB, MAPK, and TRAF6.•Targeting TLR signaling mediators might be a promising way to treat atherosclerosis.